Quantitation of glial fibrillary acidic protein in human brain tumours. by Rasmussen, S. et al.
Br. J. Cancer (1980) 41, 113
QUANTITATION OF GLIAL FIBRILLARY ACIDIC PROTEIN IN
HUMAN BRAIN TUMOURS
S. RASMUSSEN', E. BOCK'. K. WARECKA2 AND G. ALTHAGE2
Froma lThe Protein Laboratory, University of Copenhagen, Copenhagen N, Denmark, and the
2Department of NeurologyandNeuroimmunological Laboratory ofthe Medical U.niversityof
Lubeck, WestGermany
Received 18 AMay 1979 Accepted 4 September 1979
Summary.-The glial fibrillary acidic protein (GFA) content of 58 human brain
tumours was determined by quantitative immunoelectrophoresis, using mono-
specific antibody against GFA. Astrocytomas, glioblastomas, oligodendrogliomas,
spongioblastomas, ependymomas and medulloblastomas contained relatively high
amounts of GFA, up to 85 times the concentration in parietal grey substance of
normal human brain. GFA was not found in neurinomas, meningiomas, adenomas of
the hypophysis, or in a single case of metastasis of adenocarcinoma. Non-glial
tumours of craniopharyngioma and haemangioblastoma were infiltrated by reactive
astroglia and showed considerable amounts of GFA.
GLIAL FIBRILLARY ACIDIC PROTEIN
(GFA) was originally described by Eng
et al. (1971) as a major constituent of cer-
tain areas in humani brain with patho-
logical conditions characterized by an
increased content of fibrous astrocytes,
e.g. multiple-sclerosis plaques. More re-
cently the presence of GFA has been
demonstrated in normal human brain
(Uyeda et al., 1]972; Dahl & Bignami,
1973). Antisera prepared against water-
soluble GFA gave apparently specific
astroglial staining by immunohistochemi-
cal techniques (Uyeda et al., 1972; Dahl &
Bignami, 1973: Schachner et al., 1977).
Staining was confined to the cytoplasm
where especially fibrillary structures, be-
lieved to be composed of filaments with a
diameter in the 8-1Onm range and called
"intermediate filaments", stained in-
tensely. In addition GFA has been demon-
strated in cross-reacting forms in brains
of a variety of vertebrates including birds
and fish (Dahl & Bignami, 1973). In-
creased levels ofGFA inglioblastomas were
first demonstrated in our laboratory (Ditt-
mann et al., 1977) and this finding was
later verified by others (Delpech et al.,
1978; Jacque et al., 1978).
The present study, using a large number
oftumour biopsy samples, was undertaken
in order to evaluate whether the glial-
specific protein GFA could be used in the
identification and eventually in the grad-
ing of specific classes of human brain
tumours. If so, a valuable supplement to
the more subjective histological diagnosis
is at hand.
MATERIALS AND METHODS
Collection of materials and extraction of
antigens-.Tumour biopsy samples, 0-1-1-0 g
wet weight, were obtained during operation
and immediately frozen at - 20°C. All samples
were kept at this temperature until analysis.
No tumour of doubtful histology was in-
cluded in our material. The frozen samples
were thawed and cut into pieces. One piece
of each tumour was used for histological
examination. The remainder was homogen-
ized at 1:10, wet weight to volume ratio, in a
medium consisting of2% (v/v) Triton X-100,
1mM EDTA and 1:1000 (v/v) Aprotinin
(basic pancreatic trypsin inhibitor) (10,000
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KIE/ml, Novo, Copenhagen) in Tris-
barbital buffer (pH 8 6), ionic strength 0-02.
Triton X-100 was added to ensure membrane
disruption. Aprotinin and EDTA were added
to prevent proteolytic digestion. Grey sub-
stance from parietal lobes of normal human
brain, obtained at necropsy about 8 h after
death, was homogenized at 1:10, wet weight
to volume ratio, in the same medium. Homo-
genization consisted of 10 strokes in a Potter-
Elvehjelm glass-teflon homogenizer, clear-
ance 0 3-0-4 mm, at 800 rev/min. Total
protein content in homogenates was deter-
mined by the Lowry method, using bovine
serum albumin as standard. To all samples
1:10 (v/v) of a 2% (w/v) solution of sodium
dodecylsulphate was added before protein
determination.
Antibody.-GFA antigen for immunization
was prepared from normal human brain white
substance by the method of Dahl (1976),
involving adsorption to hydroxyapatite. Anti-
sera against human GFA were raised in rab-
bits, and tested for specificity as described
by Moller et al. (1978). Immunization and
isolation ofthe immunoglobulin fraction from
pooled antisera were performed by the
methods ofHarboe & Ingild (1973).
Quantitative immunoelectrophoresis.-Roc-
ket immunoelectrophoresis in agarose gel
containing 0-2% (v/v) Triton X-100 was per-
formed as described by Weeke (1973). GFA
content was expressed relative to total pro-
tein in arbitrary units (au): 1 0 au was
defined as the GFA content per g parietal
grey substance.
RESULTS
GFA was estimated in samples from 58
human brain tumours (see Fig.) grouped
on the basis ofhistology. Furthermore the
5 astrocytomas investigated were graded
according to the system ofKernohan et al.
(1979) (see Table). Two out of 58 were
non-nervous-system tumours. One ofthese
was a metastasis of an adenocarcinoma of
Tumour type No.
Glioblastoma 6 * . x * x
Astrocytoma 5 x * 0
Oligodendroglioma 5 . ®0
Spongioblastoma 7 * * 0.
Ependymoma 1 =
Medulloblastoma 2 a 0
Neurinoma 9
Meningioma 17
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FIG.-GFA concentration (in arbitrary units) in 58 human brain tumours. 1 0 au corresponds to the
amount of GFA in 1 g of parietal-lobe grey substance of normal human brain (indicated by an
arrow). Tumours affected by necrosis are indicated by x , and those infiltrated by reactive astroglia
by 0.
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TABLE.-Concentration8 of GFA in 5 a8tro-
cytomas classified on the basis of malig-
nancy. The astrocytonma of Grade II-III














unkinown origin, and the other was a
haemangioblastoma. Trace amount of
GFA was revealed in the former, while the
latter, which had a fibrous appearance,
contained - 3-4 times the reference value
(Fig.). From the figure it can be seen that
astrocytomas, glioblastomas, oligodendro-
gliomas, spongioblastomas, ependymonmas
and medulloblastomas typically con-
tained high amounts of GFA, up to 85
times the reference value. In astrocytomas
there seemed to be no correlation between
the grade of malignancy and GFA content
(Table). Neurinomas, tumours derived
from the meninges, and adenomas of the
hypophysis mostly contained only trace
amounts ofGFA. The single case ofcranio-
pharyngioma investigated showed a con-
siderable amount of GFA, 24 times the
reference value.
DISCUSSION
GFA in glioblastomas was first quanti-
fied by Dittman et al. (1977) and more
recently by Delpech et al. (1978) and
Jacque et al. (1978). In agreement with
these authors, we conclude that GFA
concentration in glioblastomas is variable
and mostly raised. In one of the glio-
blastomas reactive astrocytic elements
within the tumour mass were seen. Astro-
glia responding to trauma in the CNS
become larger and more fibrous in appear-
ance than normal astroglia (Bignami &
Dahl, 1974). The amount of GFA in these
astroglia tends to be elevated. However,
the single glioblastoma affected by reactive
gliosis contained no more GFA than the
others. Neither did necrosis have any
obvious effect on GFA concentration. Also
astrocytomas contained raised but very
variable amounts ofGFA. It has been pro-
posed that GFA concentration in gliomas
might be related to the degree of astro-
cytic differentiation, and hence to the
grade oftumour malignancy (Jacque et al.,
1978). Our results do not support this
hypothesis. Delpech et al. (1978) have also
been unable to demonstrate significant
differences between the GFA content in
astrocytomas of different grades. This
controversy may be due to the fact that
most gliomas are Grade I-II in some areas
and Grade III-IV in other areas.
Assuming GFA to be astrocyte-specific,
we were surprised that all 5 oligodendro-
gliomas in our material showed just as
high and varying GFA content as the
glioblastomas and astrocytomas. By im-
munohistochemical techniques van der
Meulen et al. (1978), in contrast to Eng &
Rubinstein (unpublished), were able to
demonstrate GFA in oligodendrogliomas.
Six out of 7 spongioblastomas investigated
showed high amounts of GFA. In one of
the spongioblastomas included in our
material, only a trace amount of GFA
could be revealed. Hovever, this tumour
was severely necrotic in some areas and
might not be representative of the group.
The single case of ependymoma in our
material contained a high concentration
of GFA. By use of immunohistochemical
methods Deck et al. (1978) and Duffy et al.
(1979) also found GFA in ependymomas.
These authors conclude that GFA is
prbsent in only a proportion of ependy-
momas and ependymal cells. The 2
medulloblastomas in our sample showed
considerable amounts of GFA. Taken
together, oligodendrogliomas, spongio-
blastomas, ependymomas and medullo-
blastomas might have an astrocytic dif-
ferentiation potential. In the case of
medulloblastomas this has been suggested
recently (Delpech et al., 1978).
In 9 neurinomas, 17 meningiomas, 3
adenomas of the hypophysis and in 1
metastasis of adenocarcinoma, mostly
only traces of GFA could be detected. In
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concordance with Jacque et al. (1978) we
found high GFA contents in a cranio-
pharyngioma and a haemangioblastoma.
Although tumours of non-glial origin do
not normally allow infiltration by reactive
astroglia, the craniopharyngioma and
haemangioblastoma in our material most
certainly contained astrocytic elements.
In conclusion all tumours of glial origin
contained high and variable amounts of
GFA in contrast to tumours of non-glial
origin. The only exceptions were the cases
of craniopharyngioma and haemangio-
blastoma, which were infiltrated by reac-
tive astroglia. However, in glial tumours,
neither necrosis nor infiltration by reactive
astroglia had any clear implication for
GFA content. This probably means that
GFA is produced by the malignant cells
within the tumour mass and not simply by
reactive astrocytes.
This work was supported by The Danish Medical
Research Council.
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